Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.
Kumagai T, Matsuki E, Inokuchi K, Ohashi K, Shinagawa A, Takeuchi J, Yoshida C, Okamoto S, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Nishiwaki K, Oba K, Sakamoto J, Sakamaki H.
Kumagai T, et al. Among authors: oba k.
Int J Hematol. 2014 Jan;99(1):41-52. doi: 10.1007/s12185-013-1483-9. Epub 2013 Dec 3.
Int J Hematol. 2014.
PMID: 24297450